Board Change • Jun 07
Less than half of directors are independent Following Director Anssi Kariola's arrival on 01 June 2026, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Chairman of the Board Vesa-Pekka Silaskivi was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Jun 04
Biohit Oyj Announces Board Appointments Biohit Oyj at its Annual General Meeting held on June 3, 2026 elected CEO Anssi Kariola, Professor Kari Syrjänen as members of the Board of Directors until the end of the next AGM. Valuation Update With 7 Day Price Move • May 28
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €2.71, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 17x in the Medical Equipment industry in Finland. Total returns to shareholders of 46% over the past three years. New Risk • Apr 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Finnish stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (53% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Market cap is less than US$100m (€41.5m market cap, or US$48.7m). Valuation Update With 7 Day Price Move • Apr 21
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to €2.73, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 16x in the Medical Equipment industry in Finland. Total returns to shareholders of 53% over the past three years. Reported Earnings • Feb 12
Full year 2025 earnings: EPS exceeds analyst expectations Full year 2025 results: EPS: €0.18 (up from €0.17 in FY 2024). Revenue: €15.7m (up 9.9% from FY 2024). Net income: €2.70m (up 5.1% from FY 2024). Profit margin: 17% (in line with FY 2024). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Medical Equipment industry in Finland. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth. Announcement • Jan 15
Biohit Oyj Announces Change in Management Team with Resignation of CTO and Appointment of New R&D Director to Management Team Biohit Oyj announced that Panu Hendolin, Chief Technology Officer (CTO) and a member of the management team of Biohit Oyj, has resigned. Kati Piironen has been appointed to the management team to succeed Mr. Hendolin. She serves as the company’s R&D Director. Ms. Piironen has been employed by Biohit since 2024. She holds a PhD in pharmaceutical chemistry, and has broad experience in product development, particularly in diagnostic technologies. Her expertise supports the further development of the company’s research and development activities to meet future needs. The change takes effect immediately. Announcement • Nov 27
Biohit Oyj, Annual General Meeting, Jun 03, 2026 Biohit Oyj, Annual General Meeting, Jun 03, 2026, at 14:00 FLE Standard Time. Valuation Update With 7 Day Price Move • Nov 12
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to €3.58, the stock trades at a trailing P/E ratio of 24x. Average trailing P/E is 28x in the Medical Equipment industry in Europe. Total returns to shareholders of 98% over the past three years. Reported Earnings • Aug 11
First half 2025 earnings: EPS and revenues miss analyst expectations First half 2025 results: EPS: €0.059 (down from €0.079 in 1H 2024). Revenue: €7.40m (flat on 1H 2024). Net income: €900.0k (down 25% from 1H 2024). Profit margin: 12% (down from 16% in 1H 2024). Revenue missed analyst estimates by 11%. Earnings per share (EPS) also missed analyst estimates by 25%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Medical Equipment industry in Finland. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth. Announcement • May 12
Bio Hit Oyj Announces Clinical Validation Study of GastroPanel Quick Test Completed in India Biohit Oyj's latest innovation, the GastroPanel® quick test, represents the most advanced technology in the non-invasive serological diagnostics and screening of patients at high risk of gastric cancer. The GastroPanel®? quick testing is intended for real-time diagnostics performed in a single patient visit and provides the same information as the GastroPanel®? ELISA test performed in a central laboratory. A clinical validation study of the GastroPanel®? rapid test was recently completed at Fortis Hospital in India, one of the countries associated with a high risk of gastric Cancer. A total of 266 volunteers took part in the study. Other significant risk factors for gastric cancer include an infection caused by Helicobacter pylori and atrophy of the stomach lining, i.e. atrophic gastritis. According to the study results, the Gastro Panel®? quick test identified moderate to severe gastric mucosal atrophy with almost 100% diagnostic accuracy and Helicobacter pylori infection with approximately 84% diagnostic accuracy. Determining the health of the stomach and the cause of upper abdominal symptoms is important because the risk of gastric cancer increases by up to 90-fold due to atrophy of the stomach lining. Furthermore, it has been estimated that of all people infected with Helicobacter pylori, which accounts for approximately 40-50% of the global population, 5% will eventually develop moderate or severe gastric mucosalphy if Helicobacter pylori eradication therapy is not administered. The GastroPanel® test, developed by Biohit in the early 2000s, provides an accurate picture of the condition of the stomach mucosa and gastric acid secretion from a blood sample. This allows scarce endoscopy resources to be allocated to those patients who need it most. The further developed GastroPanel® quick test is performed by using a blood sample taken from the fingertip, and the results become available in as little as 15 minutes. Reported Earnings • Mar 23
Full year 2024 earnings: EPS exceeds analyst expectations Full year 2024 results: EPS: €0.17 (up from €0.12 in FY 2023). Revenue: €14.3m (up 9.2% from FY 2023). Net income: €2.57m (up 39% from FY 2023). Profit margin: 18% (up from 14% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Medical Equipment industry in Finland. Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth. Reported Earnings • Feb 13
Full year 2024 earnings: EPS exceeds analyst expectations Full year 2024 results: EPS: €0.17 (up from €0.12 in FY 2023). Revenue: €14.3m (up 9.4% from FY 2023). Net income: €2.60m (up 41% from FY 2023). Profit margin: 18% (up from 14% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Medical Equipment industry in Finland. Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth. Announcement • Feb 01
BIOHIT Introduces the FAEX Sample System for Stool Sample Collection and Handling BIOHIT Oyj announced the launch of the BIOHIT FAEX Sample System, a revolutionary stool sample collection and handling solution that can be seamlessly incorporated into any diagnostic workflow. Designed for precision, efficiency and flexibility, this innovative, practical and reliable system addresses the needs of both patients and laboratories. The BIOHIT FAEX sample System combines multi-functionality with ease of use. It serves as both a standard test tube and a convenient dropper tube, enabling precise and reproducible sample dispensing for ELISAs, chemiluminescence assays, lateral flow tests and proprietary diagnostic kits. The precision-engineered collection stick ensures consistent and accurate sample collection, while a screw-tight cap with leak-proof threads promotes safe and hygienic handling, transport, storage and disposal. CE-marked and compliant with Regulation (EU) 2017/746 for In Vitro Diagnostic Devices (IVDR), the BIOHITFAEX Sample System meets the highest regulatory standards. Whether used as a standalone component or as part of a diagnostic kit, it is a versatile and efficient solution that simplifies stool sample collection and processing in any setting. New Risk • Jan 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Finnish stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (48% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (5.4% average weekly change). Market cap is less than US$100m (€37.7m market cap, or US$38.8m). Valuation Update With 7 Day Price Move • Jan 08
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to €2.83, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 16x in the Medical Equipment industry in Finland. Total returns to shareholders of 55% over the past three years. Major Estimate Revision • Dec 24
Consensus EPS estimates increase by 15%, revenue downgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from €15.1m to €14.3m. EPS estimate rose from €0.13 to €0.15. Net income forecast to grow 42% next year vs 26% growth forecast for Medical Equipment industry in Finland. Consensus price target up from €2.70 to €2.90. Share price rose 2.2% to €2.33 over the past week. Announcement • Dec 19
Biohit Oyj Lowers Earnings Guidance for 2024 Biohit Oyj lowered earnings guidance for 2024. The company is lowering its guidance for 2024 revenue. Sales in December will be below forecast due to increased tensions in Middle East. Biohit will postpone deliveries to the region as there have been delays in money transfers. New guidance for 2024: 2024 revenue will be 14.1-14.4 million EUR (growth from 2023 7.8-10.1%) and operating profit percentage 16-18%. Previous guidance for 2024 (issued February 14, 2024, reissued August 7, 2024): In line with the financial targets the company set in strategy, the company expects revenue to rise to EUR 15.1-15.7 million in 2024 and operating profit percentage to be at least 10. Announcement • Nov 28
Biohit Oyj, Annual General Meeting, Jun 04, 2025 Biohit Oyj, Annual General Meeting, Jun 04, 2025, at 14:00 FLE Standard Time. Reported Earnings • Aug 12
First half 2024 earnings: EPS exceeds analyst expectations while revenues lag behind First half 2024 results: EPS: €0.079 (down from €0.093 in 1H 2023). Revenue: €7.40m (up 14% from 1H 2023). Net income: €1.20m (down 14% from 1H 2023). Profit margin: 16% (down from 22% in 1H 2023). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 2.6%. Earnings per share (EPS) exceeded analyst estimates by 33%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Medical Equipment industry in Finland. Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Price Target Changed • Aug 09
Price target increased by 17% to €2.70 Up from €2.30, the current price target is provided by 1 analyst. New target price is 19% above last closing price of €2.26. Stock is up 8.7% over the past year. The company is forecast to post earnings per share of €0.13 for next year compared to €0.12 last year. Reported Earnings • Mar 26
Full year 2023 earnings: EPS and revenues exceed analyst expectations Full year 2023 results: EPS: €0.12 (up from €0.04 in FY 2022). Revenue: €13.1m (up 19% from FY 2022). Net income: €1.85m (up 208% from FY 2022). Profit margin: 14% (up from 5.5% in FY 2022). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 5.6%. Earnings per share (EPS) also surpassed analyst estimates by 9.1%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Medical Equipment industry in Finland. Over the last 3 years on average, earnings per share has increased by 118% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Major Estimate Revision • Feb 21
Consensus EPS estimates increase by 18% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from €14.1m to €15.3m. EPS estimate increased from €0.11 to €0.13 per share. Consensus price target up from €2.30 to €2.40. Share price fell 4.0% to €1.93 over the past week. Reported Earnings • Feb 16
Full year 2023 earnings: Revenues exceed analyst expectations Full year 2023 results: Revenue: €13.1m (up 20% from FY 2022). Net income: €1.90m (up 216% from FY 2022). Profit margin: 14% (up from 5.5% in FY 2022). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 5.6%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Medical Equipment industry in Finland. New Risk • Aug 11
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 30% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (30% accrual ratio). Minor Risk Market cap is less than US$100m (€31.4m market cap, or US$34.4m). Reported Earnings • Aug 11
First half 2023 earnings: EPS and revenues exceed analyst expectations First half 2023 results: EPS: €0.093 (up from €0.06 in 1H 2022). Revenue: €6.50m (up 6.6% from 1H 2022). Net income: €1.40m (up 56% from 1H 2022). Profit margin: 22% (up from 15% in 1H 2022). The increase in margin was primarily driven by higher revenue. Revenue exceeded analyst estimates by 12%. Earnings per share (EPS) also surpassed analyst estimates by 80%. Revenue is forecast to grow 9.3% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Medical Equipment industry in Finland. Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Announcement • Aug 10
Biohit Revises Earnings Guidance for 2023 BIOHIT revised earnings guidance for 2023. For the year, company expected revenue to be EUR 12 Million -13 Million in 2023 (2022: EUR 11 million) and EBIT to increase compared to 2022 (in 2022: EUR 1.1 million). Announcement • Jun 15
Biohit Oyj Approves Election of Vesa Silaskivi as Members of Board of Directors Biohit Oyj announced that at its AGM held on June 14, 2023, shareholders approved the election of Vesa Silaskivi as members of board of directors. Reported Earnings • Mar 27
Full year 2022 earnings released: EPS: €0.04 (vs €0.10 loss in FY 2021) Full year 2022 results: EPS: €0.04 (up from €0.10 loss in FY 2021). Revenue: €11.0m (up 17% from FY 2021). Net income: €601.0k (up €2.10m from FY 2021). Profit margin: 5.5% (up from net loss in FY 2021). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Feb 22
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to €1.74, the stock trades at a trailing P/E ratio of 43.6x. Average trailing P/E is 30x in the Medical Equipment industry in Europe. Total loss to shareholders of 35% over the past three years. Announcement • Feb 16
Biohit Oyj Provides Earnings Guidance for the Year 2023 Biohit Oyj provided earnings guidance for the year 2023. The company expects EBIT to increase in 2023 compared to 2022 (in 2022: EUR 1.1 million). Reported Earnings • Feb 16
Full year 2022 earnings released Full year 2022 results: Revenue: €11.0m (up 18% from FY 2021). Net income: €600.0k (up €2.10m from FY 2021). Profit margin: 5.5% (up from net loss in FY 2021). The move to profitability was primarily driven by higher revenue. Announcement • Dec 16
Biohit Oyj Announces Executive Changes Biohit Oyj's R&D Director PhD and Associate Professor Minna Mäki has resigned. Current Head of Technical Product Management Panu Hendolin has been appointed to new R&D Director. Hendolin has worked at Biohit as R&D and Production Director in 2007-2008, as well as 2012-2017, and he returned to the company in February 2022. In the meanwhile, Hendolin worked as Production Director at United Medix Laboratories Oy and Chief Technology Officer at Sulapac Oy. Hendolin has the degree of Ph.D. in molecular medicine. Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Kalle Härkönen was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Nov 08
Investor sentiment improved over the past week After last week's 15% share price gain to €1.76, the stock trades at a trailing P/E ratio of 52.8x. Average trailing P/E is 26x in the Medical Equipment industry in Europe. Total loss to shareholders of 45% over the past three years. Valuation Update With 7 Day Price Move • Sep 12
Investor sentiment improved over the past week After last week's 16% share price gain to €1.63, the stock trades at a trailing P/E ratio of 48.9x. Average trailing P/E is 27x in the Medical Equipment industry in Europe. Total loss to shareholders of 35% over the past three years. Announcement • Sep 03
Biohit Oyj Announces Executive Changes Biohit Oyj announced CEO Päivi Siltala has resigned. The board of directors of the company has appointed CFO Jussi Hahtela the new CEO. Hahtela will start in the new role immediately. Master of Social Sciences Jussi Hahtela (b. 1973) has worked at the company as CFO from June 2021. He has previously worked in Nordea for example as chief strategist and Head of FX sales Finland. Announcement • Aug 23
Biohit Oyj Appoints Panu Hendolin as Member of the Management Team Head of Technical Product Management Panu Hendolin has been appointed member of the Management Team of Biohit Oyj starting September 1, 2022. Hendolin is responsible for innovation and life cycle management of the medical devices. Hendolin reports to CEO Päivi Siltala. Hendolin has worked at Biohit as R&D and Production Director in 2007-2008, as well as 2012-2017, and he returned to the company in February 2022. In the meanwhile, Hendolin worked as Production Director at United Medix Laboratories Oy and Chief Technology Officer at Sulapac Oy. Reported Earnings • Aug 15
First half 2022 earnings released: EPS: €0.06 (vs €0.073 loss in 1H 2021) First half 2022 results: EPS: €0.06 (up from €0.073 loss in 1H 2021). Revenue: €6.10m (up 53% from 1H 2021). Net income: €900.0k (up €2.00m from 1H 2021). Profit margin: 15% (up from net loss in 1H 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Announcement • Aug 05
Biohit Oyj Revises Earnings Guidance for the Year 2022 Biohit Oyj revised earnings guidance for the year 2022. For the year, the company revises its EBIT to be positive in 2022 (2021: EUR -1.5 million). The previous guidance for 2022, issued on March 30, 2022. Announcement • Jun 17
Biohit Oyj Appoints Lea Paloheimo as the Chairman of the Board of Directors Biohit Oyj announced that the Board of Directors has in its meeting on June 15, 2022 elected PhD Lea Paloheimo as the Chairman of the Board of Directors. Paloheimo has been Member of the Board of Directors of Biohit Oyj since 2019. She worked with Biohit Oyj in 2001-2019, for example as Production, Product Development and Quality Director, as well as Business Development Director. Announcement • Jun 16
Biohit Oyj Elects Kalle Härkönen as Board of Director Biohit Oyj announced that at its AGM held on June 15, 2022, the shareholders elected Kalle Härkönen as board of director. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 3 highly experienced directors. 1 independent director (5 non-independent directors). Non-Independent Chairman Eero Lehti was the last independent director to join the board, commencing their role in 2009. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Feb 17
Full year 2021 earnings: Revenues in line with analyst expectations Full year 2021 results: Revenue: €9.40m (up 32% from FY 2020). Net loss: €1.50m (loss narrowed 55% from FY 2020). Revenue was in line with analyst estimates. Announcement • Feb 16
Biohit Oyj Provides Earnings Guidance for the Year 2022 Biohit Oyj provided earnings guidance for the year 2022. The company expects its 2022 profitability to improve comparing with 2021. Announcement • Feb 09
Biohit Oyj Specifies Financial Guidance for 2021 Biohit Oyj has previously estimated that 2021 revenue will grow significantly compared to 2020. No guidance has been given on profitability. After the settlement, Biohit estimates its revenue to grow by 31% to EUR 9.4 million (in 2020 EUR 7.1 million) and EBITDA to turn positive to EUR 0.5 million (in 2020 EUR -1.2 million). EBIT for the financial period of 2021 will be negative, approximately EUR -1.5 million (in 2020 EUR -3.2 million), due to depreciations from the China patents. These depreciations ended as planned in 2021. The figures are based on a preliminary financial statement, and they have not been audited. Announcement • Dec 15
Biohit Oyj Announces Recent Clinical Validation Study Confirms the Accuracy of the New-Generation GastroPanel Test in Diagnosis of Atrophic Gastritis and Helicobacter Pylori Infection A new clinical validation study from Oulu University Hospital was recently published in a widespread international cancer journal (1), confirming that new-generation GastroPanel® test is highly accurate in diagnosing atrophic gastritis and Helicobacter pylori infection in gastroscopy referral patients. GastroPanel biomarker test is a unique innovation of a Finnish biotechnology company (Biohit Oyj, Helsinki), designed for the first-line diagnosis of Helicobacter pylori (Hp) infection and atrophic gastritis (AG) among the patients with upper abdominal symptoms (dyspepsia) and esophageal reflux disease (GERD) in a simple blood test (2-6). GastroPanel® is also the only test on the market monitoring the regulatory mechanism of acid output in the stomach (7). Because Hp and AG as well as high acid output are important risk conditions for gastric and esophageal cancer, the highly informative GastroPanel® is particularly suitable for a cost-effective, population-based screening of asymptomatic individuals for the risk of gastric and esophageal cancer, as confirmed in several studies from the high- and low-risk countries (6,8-12). On the track towards the GastroPanel® quick (POC) test, a new-generation (unified) GastroPanel® test was designed harmonizing the ELISA processing conditions of the 4 biomarkers. This new test version has recently undergone the first two clinical validation studies in patients at high risk for AG, i.e., autoimmune thyroid disease (AITD) and type 1 diabetes mellitus (DM1) (13) as well as in those with high Hp-prevalence (St. Petersburg, Russia) (14). Reported Earnings • Aug 12
First half 2021 earnings released: €0.073 loss per share (vs €0.15 loss in 1H 2020) The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: €4.00m (up 33% from 1H 2020). Net loss: €1.10m (loss narrowed 52% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings. Executive Departure • May 26
President & CEO Semi Korpela has left the company On the 17th of May, Semi Korpela's tenure as President & CEO of the company ended after 9.4 years in the role. As of March 2021, Semi personally held only 14.76k shares (€34k worth at the time). Semi is the only executive to leave the company over the last 12 months. Under Semi's leadership, the company delivered a total shareholder return of 24%. Reported Earnings • Mar 29
Full year 2020 earnings released: €0.22 loss per share (vs €0.094 loss in FY 2019) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: €7.12m (down 29% from FY 2019). Net loss: €3.31m (loss widened 134% from FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance. Reported Earnings • Feb 19
Full year 2020 earnings released: €0.22 loss per share (vs €0.094 loss in FY 2019) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: €7.10m (down 29% from FY 2019). Net loss: €3.30m (loss widened 133% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 74% per year but the company’s share price has only fallen by 23% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Dec 28
New 90-day high: €2.26 The company is up 10.0% from its price of €2.06 on 29 September 2020. The Finnish market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 7.0% over the same period. Announcement • Dec 10
Biohit Oyj to Report Fiscal Year 2020 Results on Feb 17, 2021 Biohit Oyj announced that they will report fiscal year 2020 results at 9:30 AM, E. Europe Standard Time on Feb 17, 2021 Is New 90 Day High Low • Oct 21
New 90-day low: €1.99 The company is down 18% from its price of €2.41 on 23 July 2020. The Finnish market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is flat over the same period. Is New 90 Day High Low • Sep 25
New 90-day low: €2.00 The company is down 20% from its price of €2.50 on 26 June 2020. The Finnish market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is flat over the same period. 
